medRxiv preprint doi: https://doi.org/10.1101/2022.08.21.22279038; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

A pilot analysis of circulating cfRNA transcripts for the detection of lung cancer

15

Chamindi Seneviratne ^{1,2} , Amol C. Shetty ² , Xinyan Geng ³ , Carrie McCracken ² , Jessica Cornell ¹ , Kristin Mullins ^{3,4} , Feng Jiang ³ , and Sanford Stass ^{3,4,*}
¹ Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD; <u>csenevi@som.umaryland.edu</u> ;
<u>[Cornell@som.umaryland.edu</u>
² The Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD; <u>AShetty@som.umaryland.edu</u> ;
csenevi@som.umaryland.edu; cmccracken@som.umaryland.edu
³ Department of Pathology, University of Maryland School of Medicine, Baltimore, MD; <u>kmullins@som.umaryland.edu</u> ;
FJiang@som.umaryland.edu; SStass@som.umaryland.edu
⁴ Laboratories of Pathology, University of Maryland Medical Center, Baltimore, MD; <u>kmullins@som.umaryland.edu</u> ;
<u>SStass@som.umaryland.edu</u>

* Correspondence: <u>SStass@som.umaryland.edu</u>

Abstract: Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that non-16 small cell lung cancer (NSCLC) which constitute majority of lung cancers, are significantly more responsive to 17 early-stage interventions. However, the early stages are often asymptomatic, and current diagnostic methods 18 are limited in their precision and safety. The cell-free RNAs (cfRNA) circulating in plasma (Liquid biopsies) offer 19 non-invasive detection of spatial and temporal changes occurring in primary tumors since early stages. To 20 address gaps in current cfRNA knowledge base, we conducted a pilot study for comprehensive analysis of 21 transcriptome-wide changes in plasma cfRNA in NSCLC patients. Total cfRNA was extracted from archived 22 plasma collected from NSCLC patients (N=12; cases), cancer-free former smokers (N=12; control_smokers) and 23 non-smoking healthy volunteers (N=12; control_healthy). Plasma cfRNA expression levels in each sample were 24 quantified by using a tagmentation-based library preparation and sequencing. The comparisons of cfRNA 25 expression levels between cases and the two control groups revealed a total of 2537 differentially expressed 26 cfRNA enriched in 123 pathways in NSCLC patients. Of these, 222 transcripts were previously reported in 27 primary NSCLCs. Our study provides a framework for developing a blood-based assay for early detection of 28 NSCLC and warrants further validation. 29

Keywords: NSCLC; cell-free RNA; Liquid biopsies; biomarkers; smokers

1. Introduction

Lung cancers are the leading cause of cancer-related deaths in both men and women in the U.S. 33 and worldwide. Non-small cell lung cancer (NSCLC) constitutes approximately 84% of all lung cancer 34 cases, and consists of two main histological subtypes: adenocarcinoma (AC) and squamous cell 35 carcinoma (SCC) [1]. The main risk factor for developing NSCLC is smoking, which is preventable, yet 36 highly prevalent with over a billion smokers around the world [2]. Moreover, smoking and other 37 environmental pollutants interact with biological factors such as aging and genetic risk variants to 38 increase disease burden [3-6]. Furthermore, the NSCLC risk has been shown to correlate positively with 39 severity and duration of smoking, and negatively with time since smoking cessation [7, 8]. 40

Because the lung cancers are often asymptomatic in early stages, most patients are diagnosed at 41 advanced stages resulting in only about 15-20% of patients surviving 5 years after the diagnosis [6]. The 42 early-stage NSCLC are more responsive to treatment [9], and therefore, crucial to reduce mortality. At 43 present, the only recommended diagnostic method for NSCLC is detection of pulmonary nodules (PNs) 44 with low dose computed tomography (LDCT) [10]. In fact, based on data from Cancer Intervention and 45 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 5 Surveillance Modeling Network (CISNET), the US Preventive Services Task Force (USPSTF) 46

32

medRxiv preprint doi: https://doi.org/10.1101/2022.08.21.22279038; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

recommended annual screening of adults aged 50 to 80 years of age with a smoking history of 20 or 47 more pack-years, who currently smoke or quit smoking within the past 15 years [11]. This 2021 USPSTF 48 recommendation (A-50-80-20-15) was updated to expand the population eligible for LDCT screening 49 over the previous 2013 USPSTF recommendation that required smoking history of 30 or more pack-50 years (A-50-80-30-15). The LDCT has high negative predictive values, moderate sensitivity and 51 specificity, and low positive predictive values [12]. A recent meta-analysis corresponding to data from 52 84,558 participants who had a smoking history 15 or more pack-years indicated a 17% relative reduction 53 in mortality in the group screened with LDCT compared to the control group [12]. Despite these 54 encouraging statistics, there are several important limitations to using LDCT for NSCLC diagnosis. For 55 example, the high false-positive rates can lead to further testing of benign PNs with invasive diagnostic 56 and therapeutic procedures such as serial CTs, biopsy and surgery that carry their own morbidity. The 57 invasive procedures are reported to be performed in 44% of smokers with indeterminate PNs that have 58 roughly 5% probability of malignancy, and 35% of surgical resections are ultimately determined to be 59 benign diseases [13]. Another concern is the exposure to radiation with repeated LDCT. Statistical 60 modelling has predicted 1 death for every 13.0 lung-cancer related deaths avoided by LDCT with 2021 61 USPSTF recommendations, which was a 2% worsening compared to risk associated with 2013 USPSTF 62 recommendations[11]. Considering these factors, it is clinically important to develop noninvasive 63 biomarkers to distinguish malignant from benign PNs facilitating positive screening results on LDCT. 64

Recently, the concept of liquid biopsies has garnered excitement among the scientific community 65 for its' potential to provide real-time information on spatial and temporal changes in tumor markers in 66 an easily obtained peripheral blood sample [14]. Several types of biomarkers have been explored in 67 liquid biopsies as potential diagnostics with mixed results. Circulating tumor DNAs (ctDNA) have over 68 90% sensitivity and specificity for NSCLC diagnosis in patients with stage II-IV NSCLC, but around 69 50% in patients with stage I NSCLC when shedding rates are low [15]. Analysis of mutations in ctDNA 70 has also been reported to have lower sensitivity and specificity in early-stage NSCLC [16]. Therefore, 71 analysis of ctDNA-mutations or quantities appear to be more suitable for therapeutic and disease 72 monitoring in NSCLC patients, rather than the early detection. In contrast, tumors with low shedding 73 rates add cell-free RNAs (cfRNA) to blood circulation presenting with the opportunity to identify the 74 overexpressed, tumor-specific, and tumor-derived RNA signals in the blood [17]. Studies have also 75 shown that cfRNA could complement ctDNA and thus improve early diagnosis [18]. The studies of 76 cfRNA have mainly focused on either microRNAs (miRNA) or a small number of known cancer-related 77 messenger RNAs (mRNA)[19-21]. Moreover, the published studies have used large amounts of plasma 78- up to 4-5ml, for cfRNA extraction for expression analyses limiting its potential clinical use. We have 79 conducted a pilot study to explore the ability to detect cfRNA signatures of NSCLC, particularly of the 80 genes that were previously reported to be differentially expressed in lung cancer primary tissue 81 biopsies, compared to both cancer-free smokers and healthy non-smokers. 82

2. Materials and Methods

83

Study design: In this pilot study, we first compared the expression levels of plasma cfRNA obtained 84 from SCC and AC patients (N=12; cases) and cancer-free former smokers (N=12; control smokers). As 85 all patients in the case group were also heavy smokers, we included a second control group of non-86 smoking healthy individuals (N=12; control_healthy) to exclude differentially expressed cfRNAs 87 associated with smoking, rather than pathological processes underlying NSCLC. Each participant 88 provided whole blood samples as part of an umbrella protocol approved by the Institutional Review 89 Board of the University of Maryland Baltimore [UMB IRB protocol ID: HP-00040666] and the Veterans 90 Affairs Maryland Health Care System. All participants provided written informed consent to 91 participate in research con-ducted at the University of Maryland Medical Center and the Baltimore VA 92 Medical Center. Diagnosis of lung cancer was established by pathologic examination of tissues obtained 93 via surgery or biopsy. Histological diagnosis was made on bronchoscopic biopsy specimens and 94 thoracotomy according to the World Health Organization (WHO) categories. The NSCLC stage 95 classification was based on WHO classification and the International Association for the Study of Lung 96 97 Cancer staging system. The smokers consisted of former smokers who had a minimum smoking history

98

99 100

101

of 30-pack years and quit within the past 15 years. Exclusion criteria were similar to Leng et al. 2017 [8]. Demographic and clinical characteristics of the cohorts are presented in Table 1.

ruble 1. Demographie	able 1. Demographic and emilear enaluciensites								
	Cases	Control_	Control_	p-val	p-value				
	(N=12)	Smokers	Healthy	Cases	Cases vs.				
		(N=12)	(N=12)	Control_	Control_	vs.			
				Smokers	Healthy	Healthy			
Age (mean, (SD))	67.17	68.44	40.17 (4.99)	0.728	< 0.0001	< 0.0001			
	(8.99)	(10.01)							
Gender	11	9 (75)	7 (58.33)	0.3144	0.0480	0.3144			
(Male, N (%))	(91.67)								
Race	5 (4.67)	5 (4.67)	5 (4.67)	ns	ns	ns			
(Caucasian, N (%))									
Stage									
Stage I (N)	2								
Stage II (N)	5								
Stage III-IV (N)	5								
Histological type									
AC (N=6)	6								
ACC (N=6)	6								
Average plasma	1.6	1.6	1.54	ns	ns	ns			
volumes used (ml)									

Table 1: Demographic and clinical characteristics

ns – not significant.

102

103

118

Sample preparation and sequencing: Archived plasma samples were thawed at 37°C and centrifuged 104 at 16,000 x G for 30 minutes at 4°C to remove any cellular components in plasma. The supernatant was 105 extracted and centrifuged again at 13,000 x G for 30 minutes at 4°C, and store at -80°C until day of 106 cfRNA extractions. The cfRNA was extracted from archived plasma using the miRNeasy® 107 Serum/Plasma Advanced Kit (Qiagen) according to manufacturer's guidelines and were tested for RNA 108 integrity using an Agilent bioanalyzer system. Libraries were prepared using a tagmentation-based 109 method consisting of a two-step probe-assisted exome enrichment for cfRNA detection (Illumina, Inc, 110 San Diego, CA) [22]. An Illumina Exome enrichment panel that included > 425,000 probes (oligos), each 111 constructed against the NCBI37/hg19 reference genome, covering > 98% of the RefSeq exome was used 112 to pool libraries with target cfRNA of interest. The probe set was designed to capture > 214,000 targets, 113 spanning 21,415 genes of interest. Probes hybridized to target libraries were captured according to 114 protocol and amplified using a 19-cycle PCR program. Enriched libraries were then purified with 115 magnetic beads and were then sequenced using a NovaSeq 6000 system (Illumina, Inc), at a sequencing 116 depth of 100 million reads at 100bp PE length. 117

Data analyses: Raw sequence reads generated for each sample were analyzed using the CAVERN 119 analysis pipeline [23]. Read quality was assessed using the FastQC toolkit to ensure good quality reads 120 for downstream analyses. Reads were aligned to the Human reference genome GRCh38 (available from 121 *Ensembl* repository) using HISAT2, a fast splice-aware aligner for mapping next-generation sequencing 122 reads [24]. Reads were aligned using default parameters to generate the alignment BAM files. Read 123 alignments were assessed to compute gene expression counts for each gene using the HTSeq count tool 124 [25] and the Human reference annotation (GRCh38). The raw read counts were normalized for library 125 size and dispersion of gene expression. The normalized counts were utilized to assess differential 126 cfRNA expression between conditions using DESeq2. P-values were generated using Wald test 127 implemented in DESeq2 and then corrected for multiple hypothesis testing using the Benjamini-128

medRxiv preprint doi: https://doi.org/10.1101/2022.08.21.22279038; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

4 of 12

131

140

Hochberg correction method [26]. Significant differentially expressed cfRNA between conditions were 129 determined using a false discovery rate (FDR) of 5% and a minimum absolute log2(fold-change) of 1. 130

3. Results

cfRNA processing and quality control: cfRNA was extracted from all 36 samples at mean 132 concentrations of 0.111 ng/ul in cases, 0.085 ng/ul in control_smokers, and 0.151ng/ul in control_healthy 133 group. The RNA integrity numbers (RIN) ranged from 1 to 5.3. All samples had sequence reads that 134 mapped >80% to the reference sequence and mapped to exonic regions. Total Gene Abundance ranged 135 from approximately 10 to 70 million. Of these genes, 0.5-10% were Hb coding genes, 0.5-20% 136 mitochondrial genes, <0.03% ribosomal RNA (rRNA) genes, and up to 4% were other non-coding RNA 137 (ncRNA) genes. Amongst protein coding genes, the most abundant were actin, myosin, platelet-specific 138 genes, and pseudogenes. 139

Identification of differentially expressed cfRNA: Differential expression of cfRNA was analyzed after 141 excluding Hb, Mitochondrial and rRNA transcripts. As shown in Figure 1.1, a total of 1,905 (X+Y+Z) 142 cfRNA were identified to be differentially expressed in plasma samples from cases compared to the 143 two control groups. Of these, 2 cfRNA (LINC01956 and TAS2R16) were differentially expressed in 144 opposite directions in cases compared to control_smokers and control_healthy groups, and therefore 145 we have included theses in both X and Z categories in Figure 1.1: Both cfRNA were downregulated 146 compared to control_smokers and upregulated compared to control_healthy group. Another 1,377 147 (B+C+D in Figure 1.1) cfRNA that were detected in cases, were differentially expressed in the same 148direction in cancer-free smokers. 149

Next, we explored cfRNA within each subtype of cases - AC and SCC, compared to both control 150 groups irrespective of their statistical significance in the combined case group. Figure 1.2 presents all 151 cfRNA within each subtype category excluding DEGs shared with cancer-free smokers (i.e., 152 comparisons between control_smokers and control_healthy groups). Of these, a total of 452 cfRNA 153 (64.3% all DEGs in Figure 1.2) were not detected in the combined cases (X+Y+Z in Figure 1.1), but 154uniquely differentially expressed in either AC or SCC, or both but in differing directions. As depicted 155 in Figure 1.3, nearly half of all 2537 total cfRNA (1905+452) were functional protein coding genes. All 156 cfRNA included in Figure 1 are listed in Supplementary Table 1. 157



159 160

169

180

Figure 1: Distribution of NSCLC associated cfRNA. 1.1: cfRNA in plasma samples from cases. 1.2: 161 cfRNA in subtypes AC and SCC. 1.3: Distribution of NSCLC associated cfRNA within functional 162 categories. The most common pseudogene subcategories were, processed_pseudogenes (17.99%), 163 unprocessed_pseudogenes (2.89%), transcribed_unprocessed_pseudogenes (1.82%) and other subtypes 164 were present <1%. The "Other" category included the following subcategories at less than 1% 165 abundance: IG_V_genes, snoRNA, processed_transcripts, TR_V_genes, TR_J_genes, sense_intronic, 166 misc_RNA, scaRNA, sense_overlapping, IG_C_genes, TR_C_genes, 3prime_overlapping_ncRNA, 167 IG_J_genes, TEC, and TR_D_genes. 168

Literature review to identify DEGs previously reported in primary NSCLC biopsies: We performed 170 an exhaustive review of all published studies listed on National Center for Biotechnology Information 171 (NCBI)'s database for gene-specific information, using gene IDs for each of the 2537 identified DEGs. 172 Studies reporting DEGs in primary NSCLC biopsies were identified and are referenced in 173 Supplementary Table 1. Our literature review showed that 8.75% of total DEGs (N=222) have been 174 reported in primary tumor biopsies from NSCLC patients in published studies. Majority of these 175 replicated genes (N=159; 71.62%) were mRNA transcripts of protein coding genes, while some (N=37; 176 16.82%) were miRNA. Fifteen cfRNA that were differentially expressed in cases compared to both 177 control groups (category "Y" in Figure 1.1) and reported in primary NSCLC tissue biopsies are listed 178 in Table 2. 179

Pathway enrichment analysis: The cfRNA included in each category of Figure 1.1 were significantly 181 enriched in 123 pathways across the three comparison groups. The cases compared to control_smokers 182 had 1 significantly enriched pathway that was also detected in cancer-free smokers; GO:0010629 with 183 286 cfRNA in control smokers vs control healthy group (adjusted p= 0.0041) and 24 cfRNA in cases vs 184 control_smokers group (adjusted p= 5.98E-05). However, at an individual gene level, only 2 cfRNA 185 (MIR874 and MIR551B) in GO:0010629 were common to the 2 groups, both in terms of direction and 186

type. The cases vs control_smokers and cases vs control_healthy comparisons did not share any	187
significantly enriched pathways. Eighty-five pathways were commonly enriched in cases and cancer-	188
free smokers when each group was compared with the control_healthy. Details of pathways that were	189
uniquely enriched in cases compared with both control groups are presented in Table 3 below. The	190
gene IDs for cfRNA enriched within these pathways are listed in Supplementary Table 2.	191
	192
	193
	194
	195
	196
	197
	198
	199
	200
	201
	202
	203
	204
	205
	206
	207
	208
	209
	210
	211
	212
	213
	214
	215
	216

For studies on lung biopsies; padj: p-value adjusted for multiple corrections based on the number of total detected cfRNA transcripts.									
Gene.name	Gene.ID	Gene.type							References for findings
			compared to contro	ol_healthy grou	ib	compared to control_smokers group			in lung biopsies*
			log2FoldChange	p-value	p-adj	log2FoldChange	p-value	p-adj	
ENSG0000102970	CCL17	protein_coding	8.7116	1.5x10^-04	5.2x10^-03	9.1579	5.0x10^-05	1.1x10^-02	[27-29]
ENSG0000104880	ARHGEF18	protein_coding	7.2400	4.6x10^-11	1.4x10^-08	4.2579	4.7x10^-05	1.1x10^-02	[30]
ENSG00000123892	RAB38	protein_coding	-5.6801	1.0x10^-03	1.9x10^-02	-6.8853	4.6x10^-05	1.0x10^-02	[31, 32]
ENSG00000178104	PDE4DIP	protein_coding	-5.3701	1.9x10^-04	6.3x10^-03	-5.2635	1.9x10^-04	3.0x10^-02	[33, 34]
ENSG0000259571	BLID	protein_coding	-6.4355	3.0x10^-03	3.7x10^-02	-10.4897	7.4x10^-07	3.1x10^-04	[35]
ENSG0000271303	SRXN1	protein_coding	-4.8705	3.3x10^-03	3.9x10^-02	-5.9253	2.5x10^-04	3.7x10^-02	[36, 37]
ENSG0000207586	MIR135A2	miRNA	-19.6805	2.1x10^-12	8.9x10^-10	-25.9452	1.5x10^-21	3.3x10^-18	[38, 39]
ENSG0000207639	MIR193B	miRNA	-19.8578	4.3x10^-08	6.2x10^-06	-23.3468	4.0x10^-11	2.1x10^-08	[40-42]
ENSG0000207647	MIR153-1	miRNA	-17.9600	1.9x10^-07	2.3x10^-05	-25.6172	1.4x10^-14	1.1x10^-11	[43-46]
ENSG0000207763	MIR617	miRNA	22.1588	8.9x10^-10	1.8x10^-07	26.8981	2.8x10^-14	2.0x10^-11	[47]
ENSG0000207863	MIR125B2	miRNA	12.9574	1.0x10^-05	7.3x10^-04	-10.2390	2.7x10^-04	3.8x10^-02	[48-50]
ENSG00000221552	MIR1303	miRNA	23.9859	3.3x10^-11	1.1x10^-08	39.7024	2.8x10^-29	1.8x10^-25	[30, 34]
ENSG0000200478	SNORD115-41	snoRNA	-14.1259	1.2x10^-05	8.3x10^-04	-37.1348	3.8x10^-33	1.2x10^-28	[51]
ENSG0000212304	SNORD12	snoRNA	-22.5404	4.4x10^-10	1.0x10^-07	-22.3897	2.4x10^-10	1.2x10^-07	[51]
ENSG0000255717	SNHG1	processed_transcript	-4.2180	1.4x10^-03	2.3x10^-02	-5.2295	5.0x10^-05	1.1x10^-02	[52-54]

Table 2: cfRNA differentially expressed in cases compared to both control groups and confirmed by published studies

*For studies on lung biopsies; p-adj: p-value adjusted for multiple corrections based on the number of total detected cfRNA transcripts.

medRxiv preprint doi: https://doi.org/10.1101/2022.08.21.22279038; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Table 3:	Enriched pathways in cases compared to the two co	ontrol groups			
ID	Description	Comparison	No. of genes	pvalue	p.adjust
GO:0009888	tissue development	cases vs control_healthy	248	1.05241E-06	0.001336
GO:0030545	receptor regulator activity	cases vs control_healthy	85	2.14178E-06	0.002111
GO:0048018	receptor ligand activity	cases vs control_healthy	79	2.46434E-06	0.002111
GO:0032501	multicellular organismal process	cases vs control_healthy	802	2.15885E-06	0.002132
GO:0007186	G protein-coupled receptor signaling pathway	cases vs control_healthy	179	5.20986E-06	0.002827
GO:0051272	positive regulation of cellular component movement	cases vs control_healthy	84	7.89141E-06	0.003597
GO:0045165	cell fate commitment	cases vs control_healthy	46	1.96208E-05	0.006707
GO:0010454	negative regulation of cell fate commitment	cases vs control_healthy	7	2.66162E-05	0.007885
GO:0005198	structural molecule activity	cases vs control_healthy	105	2.09195E-05	0.009907
GO:0019958	C-X-C chemokine binding	cases vs control_healthy	5	2.31328E-05	0.009907
GO:0007200	phospholipase C-activating G protein-coupled receptor signaling pathway	cases vs control_healthy	22	4.56492E-05	0.011269
GO:0043503	skeletal muscle fiber adaptation	cases vs control_healthy	4	4.45314E-05	0.011269
GO:2001046	positive regulation of integrin-mediated signaling pathway	cases vs control_healthy	5	6.62839E-05	0.014261
GO:0001501	skeletal system development	cases vs control_healthy	71	8.55912E-05	0.016903
GO:0042221	response to chemical	cases vs control_healthy	513	0.000100227	0.018405
GO:0051493	regulation of cytoskeleton organization	cases vs control_healthy	73	0.000122165	0.020485
GO:0005125	cytokine activity	cases vs control_healthy	42	6.62701E-05	0.022704
GO:0042246	tissue regeneration	cases vs control_healthy	17	0.00018113	0.027754
GO:0007399	nervous system development	cases vs control_healthy	258	0.000258285	0.037022
GO:0042692	muscle cell differentiation	cases vs control_healthy	55	0.000254991	0.037022
GO:1904888	cranial skeletal system development	cases vs control_healthy	15	0.000320946	0.044566
GO:0009953	dorsal/ventral pattern formation	cases vs control_healthy	19	0.000326903	0.044695
GO:0043403	skeletal muscle tissue regeneration	cases vs control_healthy	11	0.000334573	0.044909
GO:0008154	actin polymerization or depolymerization	cases vs control_healthy	34	0.000360888	0.046481
GO:1902903	regulation of supramolecular fiber organization	cases vs control_healthy	51	0.000375061	0.047617
GO:0016442	RISC complex	cases vs control_smokers	22	7.54508E-17	6.64E-15
GO:0031332	RNAi effector complex	cases vs control_smokers	22	7.54508E-17	6.64E-15
GO:0016441	posttranscriptional gene silencing	cases vs control_smokers	23	4.44826E-15	1.62E-12
GO:0035194	posttranscriptional gene silencing by RNA	cases vs control_smokers	23	4.32051E-15	1.62E-12
GO:0035195	gene silencing by miRNA	cases vs control_smokers	23	3.22041E-15	1.62E-12
GO:0031047	gene silencing by RNA	cases vs control_smokers	23	1.20046E-14	3.28E-12
GO:0016458	gene silencing	cases vs control_smokers	23	1.50659E-13	3.29E-11
GO:0040029	regulation of gene expression, epigenetic	cases vs control_smokers	23	7.58031E-13	1.38E-10
GO:0010608	posttranscriptional regulation of gene expression	cases vs control_smokers	23	3.00277E-10	4.69E-08
GO:1990904	ribonucleoprotein complex	cases vs control_smokers	23	1.97925E-08	1.16E-06
GO:1903231	mRNA binding involved in posttranscriptional gene silencing	cases vs control_smokers	9	2.52524E-08	5.3E-06
GO:0003729	mRNA binding	cases vs control_smokers	9	1.00689E-05	0.001057

4. Discussion

Various subtypes of circulating cfRNA have been tested for early-stage detection of NSCLC. 232 Building upon these studies, we performed a comprehensive analysis of circulating plasma cfRNA 233 using next generation sequencing technologies to expand the repertoire of non-invasively measurable 234 NSCLC signatures. We identified 2537 cfRNA enriched in 123 pathways in those with a diagnosis of 235 NSCLC compared to control groups consisting of cancer-free smokers and non-smokers. Nearly half of 236 the detected cfRNA were transcripts of protein coding genes, and 222 of 2537 cfRNA (8.75%) conformed 237 to previously reported differentially expressed genes in primary tumor biopsies from NSCLC patients. 238 A majority (159 of 222) of these replicated transcripts were protein coding genes, while the rest were 239 previously reported miRNA and other non-coding RNAs. In fact, two of the snoRNAs - SNORD115-41 240 and SNORD12, were previously reported in NSCLC tissue biopsies by our group [51]. 241

Importantly, our pilot study used a workflow that can be easily adopted to develop a clinical assay 242 for profiling cfRNA using plasma volumes smaller than that were reported elsewhere. The archived 243 plasma samples were derived from whole blood collected in standard 3-6 ml EDTA collection tubes 244 routinely used in clinical care. Processing of small amounts of plasma (approximately 1.5ml) yielded 245 less than 5ng of total cfRNA, and library preparation with enrichment and sequencing was carried out 246 for efficient identification of cfRNA. Our methodology produced 200 to 350 million of sequence reads 247 per sample, with over 80% of reads mapping to exonic regions of the reference, comparable to what is 248 reported in methods that required much higher volumes of plasma [55]. 249

229 230

231

This study has several limitations. First, biological factors such as gender and age have been shown 250 to play a major role in development and prognosis of lung cancers [56]. For example, women smokers 251 have greater risk for developing lung cancer compared to men who smoke, presumably due to 252 underlying genetic and other biological differences between men and women [57, 58]; the AC subtype 253 predominates in women, whereas SCC are more common in men [59]; and individuals aged 65 and 254 older are at greater risk of developing lung cancers[56]. The modest sample size in this pilot project 255 limited our ability to explore moderating effects of these biological factors on our findings. This is 256 particularly true of the subtype analyses that revealed 452 differentially expressed cfRNA between AC 257 and SCC groups that consisted of small numbers of patients. It should also be noted that in our analysis, 258 both groups of smokers - with and without cancer, were significantly older than the non-smoking 259 control group, possibly altering the number of cfRNA that were found to be associated with NSCLC 260 (see Figure 1.1). Second, we were not able to test the tissue specificity of the identified cfRNA because 261 of the unavailability of lung tissue biopsies from the included participants for direct comparisons with 262 plasma cfRNA. Nevertheless, we have utilized two control groups to adjust for confounding effects of 263 smoking on cfRNA expression levels and applied conservative statistical thresholds of 5% FDR and a 264 minimum of 2-fold change difference in expression level between conditions to reduce false positive 265 findings. Furthermore, the fact that we were able to detect cfRNA of hundreds of previously reported 266 RNA transcripts from primary NSCLC biopsies, is indeed promising. 267

In summary, we have presented transcriptome-wide cfRNA profiling using small volumes of 268 plasma providing a framework for developing a non-invasive (blood-based) assay for potentially early 269 detection, diagnosis, and monitoring of NSCLC. Further studies are required for evaluation of our 270 methodology and its clinical application. 271

272

Supplementary Materials: The following supporting information can be downloaded at: [],	273
Supplementary Table 1: Differentially expressed cfRNA	274
Supplementary Table 2: Genes included in enriched pathways	275
	276

Author Contributions: Conceptualization, C.S., A.C.S., F.J., K.M. and S.F.; methodology, C.S., A.C.S., F.J., and S.F.; 277 formal analysis, A.C.S. and C.M.; resources, X.X.; data curation, C.S., A.C.S., X.G., C.M. and J.C.; writing-original 278 draft preparation, C.S.; writing-review and editing, A.C.S., F.J., K.M. and S.F.; supervision, C.S., A.C.S., F.J., and 279 S.F.; funding acquisition, S.F.. All authors have read and agreed to the published version of the manuscript 280

Funding: This research was funded by NCI-U24CA11509-01 (SS), FDA-5U01FD005946-06(FJ), and NCI-281 UH2CA229132 (FJ). 282

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki 283 and approved by the Institutional Review Board (or Ethics Committee) of the University of Maryland Baltimore 284 [UMB IRB protocol ID: HP-00040666] and the Veterans Affairs Maryland Health Care System [protocol ID: VA-285 00040666]. 286

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Acknowledgments: Authors would like to thank Dan Gheba and Tara Kesteloot for their expert advice with 289 developing the assays, John Sivinski for his assistance with sample processing, and Dr. Lisa Sadzewicz and Sandra 290 Ott for advice and assistance with two-step sequencing. 291

Conflicts of Interest: The authors declare no conflict of interest.

292 293

287 288

References 294 1. American Cancer Society. Facts & Figures 2022. American Cancer Society. Atlanta, Ga., 2022. 295 2. WHO global report on trends in prevalence of tobacco use 2000-2025. Fourth ed. 2021, Geneva: World Health 296 Organization. 297

3.	Li, Y., et al., Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer	298
	risk. Hum Mol Genet, 2022.	299
4.	Besaratinia, A., A. Caceres, and S. Tommasi, DNA Hydroxymethylation in Smoking-Associated Cancers. Int J	300
	Mol Sci, 2022. 23 (5).	301
5.	Huang, Y., et al., Air Pollution, Genetic Factors, and the Risk of Lung Cancer: A Prospective Study in the UK	302
	<i>Biobank</i> . Am J Respir Crit Care Med, 2021. 204 (7): p. 817-825.	303
6.	Bade, B.C. and C.S. Dela Cruz, Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med,	304
	2020. 41 (1): p. 1-24.	305
7.	Leduc, C., et al., Comorbidities in the management of patients with lung cancer. Eur Respir J, 2017. 49(3).	306
8.	Campling, B.G., et al., Spontaneous smoking cessation before lung cancer diagnosis. J Thorac Oncol, 2011. 6(3):	307
	p. 517-24.	308
9.	Siegel, R.L., et al., Cancer Statistics, 2021. CA Cancer J Clin, 2021. 71(1): p. 7-33.	309
10.	Force., U.S.P.S.T., Final Update Summary: Lung Cancer: Screening	310
	https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-	311
	screening., July 2015.	312
11.	Force, U.S.P.S.T., et al., Screening for Lung Cancer: US Preventive Services Task Force Recommendation	313
	Statement. JAMA, 2021. 325(10): p. 962-970.	314
12.	Jonas, D.E., et al., Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report	315
	and Systematic Review for the US Preventive Services Task Force. JAMA, 2021. 325(10): p. 971-987.	316
13.	Tanner, N.T., et al., Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter	317
	<i>Observational Study.</i> Chest, 2015. 148 (6): p. 1405-1414.	318
14.	Pinzani, P., et al., Updates on liquid biopsy: current trends and future perspectives for clinical application in solid	319
	tumors. Clin Chem Lab Med, 2021. 59(7): p. 1181-1200.	320
15.	Li, R.Y. and Z.Y. Liang, Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and	321
	treatment response. Chin Med J (Engl), 2020. 133(20): p. 2476-2485.	322
16.	Gale, D., et al., Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell	323
	<i>lung cancer</i> . Ann Oncol, 2022. 33 (5): p. 500-510.	324
17.	Larson, M.H., et al., A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-	325
	specific biomarkers for cancer detection. Nat Commun, 2021. 12(1): p. 2357.	326
18.	Sorber, L., et al., Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation	327
	Protocol. Cancers (Basel), 2019. 11(4).	328
19.	Muller, S., et al., Circulating MicroRNAs as Potential Biomarkers for Lung Cancer. Recent Results Cancer Res,	329
	2020. 215 : p. 299-318.	330
20.	de Fraipont, F., et al., Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic	331
	Response in the Liquid Biopsies of Lung Cancer Patients. Front Genet, 2019. 10: p. 390.	332
21.	Peng, W., et al., Diagnostic and Prognostic Potential of Circulating Long Non-Coding RNAs in Non Small Cell	333
	Lung Cancer. Cell Physiol Biochem, 2018. 49(2): p. 816-827.	334
22.	https://www.illumina.com/products/by-type/sequencing-kits/library-prep-kits/rna-prep-	335
	enrichment.html.	336
23.	Shetty, A.C., et al., CAVERN: Computational and visualization environment for RNA-seq analyses. 69th Annual	337
	Meeting. Houston, Texas: American Society of Human Genetics., 2019.	338

24.	Kim, D., et al., Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol 2019 37 (8): p. 907-915	339 340
25	Andere S. P.T. Dull and W. Huber. HTSea, a Duthen framework to work with high throughout comparing data	241
20.	Bioinformatics 2015 31(2): p. 166-9	341
26	Boniamini V and V Hochborg Controlling the Falce Discovery Pate: A Practical and Powerful Amroach to	242
20.	Multiple Testing, Journal of the Royal Statistical Society, Series B (Methodological), 1995, 57(1): p. 289–300	343
27	Vamashita S et al. Combination of n53 AIP1 and survivin expression is a nonverful prognostic marker in non-	345
27.	small coll lung cancer. I Evn Clin Cancer Res. 2009. 28: p. 22	345
28	Ye T et al. Chemokine CCL17 Affects Local Immune Infiltration Characteristics and Early Prognosis Value of	340
20.	Lung Adenocarcinoma Front Cell Dev Biol 2022 10: p. 816927	348
29	Yang Let al Circular RNA CHST15 Spanges miR-155-5n and miR-194-5n to Promote the Immune Escape of	349
27.	Lung Cancer Cells Mediated by PD-L1 Front Oncol 2021 11: p 595609	350
30	Song C et al Expression of n114RhoGEE predicts lumph node metastasis and noor survival of sauamous-cell	351
00.	lung carcinoma natients Tumour Biol 2013 34 (3): p 1925-33	352
31	Hsieh, LL, et al., RAB38 is a notential prognostic factor for tumor recurrence in non-small cell lung cancer. Oncol	353
01.	Lett. 2019. 18(3): p. 2598-2604	354
32.	Chang, I.W., et al., Comparison of genomic signatures of non-small cell lung cancer recurrence between two	355
	microarray platforms. Anticancer Res. 2012. 32 (4): p. 1259-65.	356
33.	Weng, T.Y., et al., Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and	357
	a Systematic-Analysis of Microarray Databases. PLoS One, 2016. 11 (8): p. e0161007.	358
34.	Li, S., et al., <i>Sequencing study on familial lung squamous cancer</i> . Oncol Lett, 2015. 10 (4): p. 2634-2638.	359
35.	Wang, H., et al., Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK	360
	signaling pathways in non-small cell lung cancer. Int J Biochem Cell Biol, 2018. 94 : p. 98-106.	361
36.	Li, Z., et al., miRNA-124 modulates lung carcinoma cell migration and invasion. Int J Clin Pharmacol Ther,	362
	2016. 54 (8): p. 603-12.	363
37.	Wei, Q., et al., Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation	364
	of specific phosphokinase signaling. Proc Natl Acad Sci U S A, 2011. 108 (17): p. 7004-9.	365
38.	Zhang, Y., et al., ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and	366
	<i>apoptosis</i> . Tumour Biol, 2014. 35 (6): p. 5701-7.	367
39.	Wang, N. and T. Zhang, Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer	368
	to Gefitinib by Targeting TRIM16. Oncol Res, 2018. 26(7): p. 1005-1014.	369
40.	Hu, F., et al., Lung adenocarcinoma resistance to therapy with EGFRtyrosine kinase inhibitors is related to	370
	increased expression of cancer stem cell markers SOX2, OCT4 and NANOG. Oncol Rep, 2020. 43(2): p. 727-735.	371
41.	Choi, K.H., et al., Dual-strand tumor suppressor miR-193b-3p and -5p inhibit malignant phenotypes of lung	372
	cancer by suppressing their common targets. Biosci Rep, 2019. 39 (7).	373
42.	She, K., et al., miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression	374
	in non-small cell lung cancer. Cell Prolif, 2018. 51(1).	375
43.	Chen, W.J., et al., MicroRNA-153 expression and prognosis in non-small cell lung cancer. Int J Clin Exp Pathol,	376
	2015. 8 (7): p. 8671-5.	377
44.	Yuan, Y., et al., Suppression of AKT expression by miR-153 produced anti-tumor activity in lung cancer. Int J	378
	Cancer, 2015. 136 (6): p. 1333-40.	379

45.	Zhang, W., et al., Expressions of connexin 32 and 26 and their correlation to prognosis of non-small cell lung	380
	cancer. Ai Zheng, 2009. 28(2): p. 173-6.	381
46.	Shan, N., et al., MiR-153 inhibits migration and invasion of human non-small-cell lung cancer by targeting	382
	ADAM19. Biochem Biophys Res Commun, 2015. 456(1): p. 385-91.	383
47.	Kim, H.K., et al., miR-592 and miR-552 can distinguish between primary lung adenocarcinoma and colorectal	384
	cancer metastases in the lung. Anticancer Res, 2014. 34(5): p. 2297-302.	385
48.	Huang, S.P., et al., Downregulation of miR-125b-5p and Its Prospective Molecular Mechanism in Lung Squamous	386
	Cell Carcinoma. Cancer Biother Radiopharm, 2022. 37(2): p. 125-140.	387
49.	Wang, J., et al., Expression and clinical evidence of miR-494 and PTEN in non-small cell lung cancer. Tumour	388
	Biol, 2015. 36 (9): p. 6965-72.	389
50.	Wang, M., et al., High expression of kinesin light chain-2, a novel target of miR-125b, is associated with poor	390
	clinical outcome of elderly non-small-cell lung cancer patients. Br J Cancer, 2015. 112(5): p. 874-82.	391
51.	Gao, L., et al., Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep	392
	<i>sequencing</i> . Int J Cancer, 2015. 136 (6): p. E623-9.	393
52.	Zhou, Q., et al., A novel lncRNA-miRNA-mRNA competing endogenous RNA regulatory network in lung	394
	adenocarcinoma and kidney renal papillary cell carcinoma. Thorac Cancer, 2021. 12(19): p. 2526-2536.	395
53.	Tan, J., et al., Integrative Analysis of Three Novel Competing Endogenous RNA Biomarkers with a Prognostic	396
	Value in Lung Adenocarcinoma. Biomed Res Int, 2020. 2020: p. 2837906.	397
54.	Shi, S.L. and Z.H. Zhang, Long non-coding RNA SNHG1 contributes to cisplatin resistance in non-small cell	398
	lung cancer by regulating miR-140-5p/Wnt/beta-catenin pathway. Neoplasma, 2019. 66 (5): p. 756-765.	399
55.	Rasmussen, M., et al., RNA profiles reveal signatures of future health and disease in pregnancy. Nature, 2022.	400
	601 (7893): p. 422-427.	401
56.	Leiro-Fernandez, V., et al., Predicting delays in lung cancer diagnosis and staging. Thorac Cancer, 2019. 10(2):	402
	p. 296-303.	403
57.	Hellyer, J.A. and M.I. Patel, Sex disparities in lung cancer incidence: validation of a long-observed trend. Transl	404
	Lung Cancer Res, 2019. 8(4): p. 543-545.	405
58.	Molina, A.J., et al., Trends in Lung Cancer Incidence in a Healthcare Area. Arch Bronconeumol, 2015. 51(11):	406
	p. e53-5.	407
59.	Pesch, B., et al., Cigarette smoking and lung cancerrelative risk estimates for the major histological types from a	408
	pooled analysis of case-control studies. Int J Cancer, 2012. 131(5): p. 1210-9.	409
		410
		411